Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics (Nasdaq: MCRB) announced that Eric Shaff, President and CEO, will discuss the company at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 9:00 a.m. ET. A webcast replay will be available on the company's website two hours post-event and will be archived for 21 days.

Seres Therapeutics specializes in microbiome therapeutics with its SER-109 program being a first-ever positive pivotal clinical result for a targeted microbiome drug candidate. The company is also advancing SER-301 and SER-155 in clinical studies.

Seres Therapeutics (Nasdaq: MCRB) announced its second quarter 2021 financial results, reporting a net loss of $48.3 million, up from $20.7 million year-over-year, primarily due to increased clinical expenses. The company highlighted significant progress with SER-109, nearing target enrollment for its safety study, and plans to file a Biologics License Application to obtain FDA approval. A license agreement with Nestlé Health Science will bolster funding and commercialization efforts for SER-109. However, SER-287's Phase 2b trial for ulcerative colitis did not meet primary endpoints, leading to the closure of parts of the study.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on August 3, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 results and provide a general business update. Interested parties can join by dialing 844-277-9450 (domestic) or 336-525-7139 (international), using conference ID 6519859. The company is a leader in microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results and receiving Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infection.

Seres Therapeutics, Inc. (Nasdaq: MCRB) held a conference call to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 for mild-to-moderate ulcerative colitis. The company has also advanced SER-109 for recurrent C. difficile infection, achieving positive pivotal clinical results and receiving Breakthrough Therapy and Orphan Drug designations from the FDA. Current evaluations include SER-301 and SER-155 in ongoing Phase 1b studies. The press release includes forward-looking statements highlighting potential challenges in profitability and clinical development.

Seres Therapeutics (MCRB) announced topline results from its Phase 2b ECO-RESET study of SER-287 for mild-to-moderate ulcerative colitis. The study failed to meet its primary endpoint for improving clinical remission rates compared to placebo, with remission rates of 10.3% and 10.6% for full and step-down doses respectively, against 11.6% for placebo. Adverse events were reported in 67.6% of subjects in the active treatment arms. Following these results, the company will close the open label portions of the study and focus on advancing SER-109, SER-301, and their early-stage pipeline.

Seres Therapeutics, Inc. (Nasdaq: MCRB) has partnered with Nestlé Health Science to co-commercialize SER-109, a microbiome therapy targeting recurrent Clostridioides difficile infection, in the U.S. and Canada. Seres will receive $175 million upfront and $125 million upon FDA approval, plus up to $225 million in sales milestones. Upon commercialization, Seres will earn 50% of profits. SER-109 aims to be the first FDA-approved microbiome therapy, with promising clinical results indicating a 27% absolute reduction in CDI recurrence. A Joint Steering Committee will oversee collaboration activities.

Seres Therapeutics (Nasdaq: MCRB) will host a virtual investor event on June 21, 2021, from 8:30 a.m. to 10:00 a.m. ET, to discuss its investigational therapies SER-287 and SER-301 for ulcerative colitis (UC). Management and Dr. Stephen Hanauer will highlight the UC patient burden and the need for new treatments. SER-287 is in a Phase 2b trial for active mild-to-moderate UC, with data expected mid-2021. SER-301 is under evaluation in a Phase 1b study. Interested participants can join via the company's website or conference call.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a microbiome therapeutics leader, announced that its Chief Commercial and Strategy Officer, Terri Young, Ph.D., will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 1:00 p.m. ET. The presentation will be accessible via an audio webcast on Seres’ website and will be archived for 21 days post-event. Seres is developing a novel class of multifunctional bacterial therapies, with its SER-109 program targeting recurrent C. difficile infection and SER-287 aimed at pediatric ulcerative colitis.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that the FDA has approved the IND application for SER-155, an investigational microbiome therapeutic aimed at reducing gastrointestinal infections in immunocompromised patients. The Phase 1b study will include around 70 patients to assess the safety and efficacy of SER-155 in preventing infections and graft-versus-host disease (GvHD) post-allogeneic hematopoietic stem cell transplantation (HSCT). SER-155 has potential to significantly impact treatment outcomes for patients facing serious antibiotic-resistant infections.